LSTA

Business Context and Reporting Period

This Form 10-K covers Corniche Group Incorporated (trading as "LISATA THERAPEUTICS, INC." in the request metadata, though the filing identifies the registrant as Corniche Group) for the fiscal year ended December 31, 2002. The Company historically operated an internet-based extended warranty business (WarrantySuperstore.com) and a reinsurance subsidiary (Stamford), both of which were discontinued or sold. As of the filing date, the Company had no employees and was in a development stage, pursuing a new business plan to enter the medical/biotech sector under the name "Phase III Medical, Inc."

Key Financial Metrics

Note: 2002 cash flow from operations was positive primarily due to the sale of marketable securities ($1.5M) and non-cash adjustments, not operating profitability.

Material Changes vs. Prior Period

• Revenue Decline: Earned revenues decreased 24% to $81,000 in 2002 from $107,000 in 2001, as the Company wound down its warranty business and recognized only deferred revenue from prior contracts.
• Expense Reduction: Selling, general, and administrative expenses dropped 44.5% to $912,000 in 2002 from $1.64 million in 2001, driven by the closure of Texas office facilities and reduced payroll.
• Impairment Charges: The Company recorded a $54,732 impairment charge for property and equipment in 2002. In 2001, a $305,333 charge was recorded for capitalized software.
• Asset Composition: Total assets decreased by 35% to $1.18 million. The primary asset is now a $1.25 million note receivable from StrandTek (net of a $250,000 allowance), whereas 2001 assets were heavily weighted toward marketable securities.
• Liquidity Crisis: Working capital turned negative, moving from a surplus of $1.08 million in 2001 to a deficit of $82,000 in 2002.

Outlook, Risks, and Management Commentary

Going Concern Doubt: The independent auditors have issued a report stating that substantial doubt exists regarding the Company's ability to continue as a going concern. The Company has no cash-generating operations, a capital deficiency of $823,895, and current liabilities exceeding current assets.

New Business Strategy: In February 2003, the Company appointed Mark Weinreb as CEO to pivot into the medical/biotech sector ("Phase III Medical, Inc."). The plan involves acquiring or partnering with biotech firms, owning drug rights, or acquiring royalty streams. This strategy requires significant new capital.

Financing Needs: The Company has no cash to settle approximately $232,000 in currently due liabilities. It has deferred $524,000 in other liabilities until 2005 contingent on financing success. The Company is actively pursuing a private placement of promissory notes (up to $250,000) and equity financing.

Legal Contingency: The Company's primary asset is a $1.25 million note receivable from StrandTek, which defaulted in July 2002. While the Company obtained partial summary judgment in February 2003, collection is not assured, and the defendants have filed counterclaims.

Investor Verification Checklist

• Cash Position: Verify the current cash balance (reported as ~$19,000 at year-end) and the status of the $232,000 in immediate liabilities.
• StrandTek Litigation: Confirm the status of the collection efforts on the $1.25 million note receivable and the outcome of the pending summary judgment motion scheduled for April 2003.
• Financing Progress: Determine if the Company has successfully raised the necessary capital through the March 2003 debt offering or subsequent equity placements to fund the new medical business plan.
• Preferred Stock Obligations: Review the status of the 681,174 shares of Series A Preferred Stock and the $385,512 in accrued dividends, which may be redeemable or convertible.
• Management Execution: Assess the progress of the new CEO in securing business partners or acquisitions in the biotech sector, as the Company currently has no revenue-generating operations.